Abstract
Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 222-226 |
| Number of pages | 5 |
| Journal | European Journal of Haematology |
| Volume | 52 |
| Issue number | 4 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- plasma-exchange
- refractory disease
- TTP
- vincristine
ASJC Scopus subject areas
- Hematology
Cite this
Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. / Bobbio-Pallavicini, E.; Porta, C.; Centurioni, R.; Gugliotta, L.; Vianelli, N.; Tacconi, F.; Billio, A.; Ascari, E.; Prinoth, O.; Rubertelli, M.; Ongaro, G.; Rodeghiero, F.; Perotti, C.; Busnach, G.; Cambie, G.; Canevari, A.; Carotenuto, M.; Leda, G.; Bertrand, G.
In: European Journal of Haematology, Vol. 52, No. 4, 1994, p. 222-226.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange
AU - Bobbio-Pallavicini, E.
AU - Porta, C.
AU - Centurioni, R.
AU - Gugliotta, L.
AU - Vianelli, N.
AU - Tacconi, F.
AU - Billio, A.
AU - Ascari, E.
AU - Prinoth, O.
AU - Rubertelli, M.
AU - Ongaro, G.
AU - Rodeghiero, F.
AU - Perotti, C.
AU - Busnach, G.
AU - Cambie, G.
AU - Canevari, A.
AU - Carotenuto, M.
AU - Leda, G.
AU - Bertrand, G.
PY - 1994
Y1 - 1994
N2 - Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.
AB - Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TPP patients resistant to conventional plasma-exchange and pharmacologic therapy.
KW - plasma-exchange
KW - refractory disease
KW - TTP
KW - vincristine
UR - http://www.scopus.com/inward/record.url?scp=0028225739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028225739&partnerID=8YFLogxK
M3 - Article
C2 - 8005232
AN - SCOPUS:0028225739
VL - 52
SP - 222
EP - 226
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 4
ER -